SK9862003A3 - A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis - Google Patents
A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis Download PDFInfo
- Publication number
- SK9862003A3 SK9862003A3 SK986-2003A SK9862003A SK9862003A3 SK 9862003 A3 SK9862003 A3 SK 9862003A3 SK 9862003 A SK9862003 A SK 9862003A SK 9862003 A3 SK9862003 A3 SK 9862003A3
- Authority
- SK
- Slovakia
- Prior art keywords
- bisphosphonate
- medicament
- ester
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
- 206010031264 Osteonecrosis Diseases 0.000 title claims abstract description 82
- 239000003814 drug Substances 0.000 title claims abstract description 81
- 238000011282 treatment Methods 0.000 title claims abstract description 35
- 229940079593 drug Drugs 0.000 title abstract description 19
- 229940122361 Bisphosphonate Drugs 0.000 claims abstract description 91
- 150000004663 bisphosphonates Chemical class 0.000 claims abstract description 87
- 201000010099 disease Diseases 0.000 claims abstract description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 17
- 210000000988 bone and bone Anatomy 0.000 claims description 84
- 150000002148 esters Chemical class 0.000 claims description 43
- 150000003839 salts Chemical class 0.000 claims description 43
- 201000009859 Osteochondrosis Diseases 0.000 claims description 40
- 238000000034 method Methods 0.000 claims description 40
- 208000007656 osteochondritis dissecans Diseases 0.000 claims description 31
- 229960004276 zoledronic acid Drugs 0.000 claims description 25
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical group OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 claims description 24
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- 208000027414 Legg-Calve-Perthes disease Diseases 0.000 claims description 15
- 210000000689 upper leg Anatomy 0.000 claims description 13
- VMMKGHQPQIEGSQ-UHFFFAOYSA-N minodronic acid Chemical compound C1=CC=CN2C(CC(O)(P(O)(O)=O)P(O)(O)=O)=CN=C21 VMMKGHQPQIEGSQ-UHFFFAOYSA-N 0.000 claims description 12
- 229950011129 minodronic acid Drugs 0.000 claims description 12
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 claims description 11
- 229940062527 alendronate Drugs 0.000 claims description 11
- 230000006378 damage Effects 0.000 claims description 11
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 claims description 11
- 229940046231 pamidronate Drugs 0.000 claims description 11
- 238000002054 transplantation Methods 0.000 claims description 11
- 210000000845 cartilage Anatomy 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 claims description 9
- 229940015872 ibandronate Drugs 0.000 claims description 9
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 claims description 8
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 claims description 8
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 claims description 8
- LWRDQHOZTAOILO-UHFFFAOYSA-N incadronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)NC1CCCCCC1 LWRDQHOZTAOILO-UHFFFAOYSA-N 0.000 claims description 8
- 229950006971 incadronic acid Drugs 0.000 claims description 8
- 230000000921 morphogenic effect Effects 0.000 claims description 8
- 229940089617 risedronate Drugs 0.000 claims description 8
- DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 claims description 7
- UGEPSJNLORCRBO-UHFFFAOYSA-N [3-(dimethylamino)-1-hydroxy-1-phosphonopropyl]phosphonic acid Chemical compound CN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O UGEPSJNLORCRBO-UHFFFAOYSA-N 0.000 claims description 7
- 229960002286 clodronic acid Drugs 0.000 claims description 7
- 229940009626 etidronate Drugs 0.000 claims description 7
- PUUSSSIBPPTKTP-UHFFFAOYSA-N neridronic acid Chemical compound NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O PUUSSSIBPPTKTP-UHFFFAOYSA-N 0.000 claims description 7
- 229950010733 neridronic acid Drugs 0.000 claims description 7
- 229940019375 tiludronate Drugs 0.000 claims description 7
- -1 zoledronic acid bisphosphonate Chemical class 0.000 claims description 7
- 239000003102 growth factor Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 210000004233 talus Anatomy 0.000 claims description 6
- 239000004606 Fillers/Extenders Substances 0.000 claims description 5
- 230000006837 decompression Effects 0.000 claims description 5
- 210000001137 tarsal bone Anatomy 0.000 claims description 5
- 210000000707 wrist Anatomy 0.000 claims description 5
- 206010058112 Chondrolysis Diseases 0.000 claims description 4
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims description 3
- 101001076292 Homo sapiens Insulin-like growth factor II Proteins 0.000 claims description 3
- 102100037852 Insulin-like growth factor I Human genes 0.000 claims description 3
- 102100025947 Insulin-like growth factor II Human genes 0.000 claims description 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 3
- 230000000735 allogeneic effect Effects 0.000 claims description 3
- 210000001872 metatarsal bone Anatomy 0.000 claims description 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 3
- 210000002303 tibia Anatomy 0.000 claims description 3
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 claims description 2
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 claims description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 2
- 229940112869 bone morphogenetic protein Drugs 0.000 claims description 2
- 229940126864 fibroblast growth factor Drugs 0.000 claims description 2
- 210000002758 humerus Anatomy 0.000 claims description 2
- 102000008137 Bone Morphogenetic Protein 4 Human genes 0.000 claims 2
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 claims 2
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 claims 2
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims 2
- IWLDTXOHXPDPQG-UHFFFAOYSA-L disodium;hydroxy-[1-hydroxy-1-[hydroxy(oxido)phosphoryl]-3-pyrrolidin-1-ylpropyl]phosphinate Chemical compound [Na+].[Na+].OP(=O)(O)C(P([O-])([O-])=O)(O)CCN1CCCC1 IWLDTXOHXPDPQG-UHFFFAOYSA-L 0.000 claims 2
- 229940029303 fibroblast growth factor-1 Drugs 0.000 claims 2
- 101150061927 BMP2 gene Proteins 0.000 claims 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 claims 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims 1
- 101150067309 bmp4 gene Proteins 0.000 claims 1
- 230000008468 bone growth Effects 0.000 claims 1
- 230000011164 ossification Effects 0.000 description 20
- 206010017076 Fracture Diseases 0.000 description 16
- 208000010392 Bone Fractures Diseases 0.000 description 15
- 239000002253 acid Substances 0.000 description 12
- 238000001356 surgical procedure Methods 0.000 description 12
- 241000700159 Rattus Species 0.000 description 11
- 230000000694 effects Effects 0.000 description 9
- 230000001338 necrotic effect Effects 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 210000002745 epiphysis Anatomy 0.000 description 8
- 210000002436 femur neck Anatomy 0.000 description 8
- 210000004394 hip joint Anatomy 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 210000001188 articular cartilage Anatomy 0.000 description 5
- 230000036407 pain Effects 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 4
- 241000906034 Orthops Species 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 201000008482 osteoarthritis Diseases 0.000 description 4
- 238000004321 preservation Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 3
- 208000007848 Alcoholism Diseases 0.000 description 3
- 241000131317 Capitulum Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010023204 Joint dislocation Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000036770 blood supply Effects 0.000 description 3
- 239000000316 bone substitute Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000003862 glucocorticoid Substances 0.000 description 3
- 210000004349 growth plate Anatomy 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000011541 total hip replacement Methods 0.000 description 3
- 230000000472 traumatic effect Effects 0.000 description 3
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 208000030016 Avascular necrosis Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 229930105110 Cyclosporin A Natural products 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- 206010011951 Decompression Sickness Diseases 0.000 description 2
- 206010013654 Drug abuse Diseases 0.000 description 2
- 208000015872 Gaucher disease Diseases 0.000 description 2
- 208000023661 Haematological disease Diseases 0.000 description 2
- 206010019663 Hepatic failure Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 206010001584 alcohol abuse Diseases 0.000 description 2
- 208000025746 alcohol use disease Diseases 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 210000003423 ankle Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000033558 biomineral tissue development Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 238000010322 bone marrow transplantation Methods 0.000 description 2
- 238000007469 bone scintigraphy Methods 0.000 description 2
- DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000004568 cement Substances 0.000 description 2
- 210000003679 cervix uteri Anatomy 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- 235000019504 cigarettes Nutrition 0.000 description 2
- 210000003109 clavicle Anatomy 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 229930182912 cyclosporin Natural products 0.000 description 2
- 208000030172 endocrine system disease Diseases 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 210000001624 hip Anatomy 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 208000007903 liver failure Diseases 0.000 description 2
- 231100000835 liver failure Toxicity 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 239000013521 mastic Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229960002378 oftasceine Drugs 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000000399 orthopedic effect Effects 0.000 description 2
- 210000000963 osteoblast Anatomy 0.000 description 2
- 210000002997 osteoclast Anatomy 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 210000004560 pineal gland Anatomy 0.000 description 2
- 239000004633 polyglycolic acid Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000000250 revascularization Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 208000007056 sickle cell anemia Diseases 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000003351 stiffener Substances 0.000 description 2
- 210000005065 subchondral bone plate Anatomy 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229950003937 tolonium Drugs 0.000 description 2
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 2
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 229920002972 Acrylic fiber Polymers 0.000 description 1
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 206010070918 Bone deformity Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 description 1
- FMTDIUIBLCQGJB-UHFFFAOYSA-N Demethylchlortetracyclin Natural products C1C2C(O)C3=C(Cl)C=CC(O)=C3C(=O)C2=C(O)C2(O)C1C(N(C)C)C(O)=C(C(N)=O)C2=O FMTDIUIBLCQGJB-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010061209 Hip deformity Diseases 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 102000004067 Osteocalcin Human genes 0.000 description 1
- 108090000573 Osteocalcin Proteins 0.000 description 1
- 208000002804 Osteochondritis Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000020201 Primary bone dysplasia Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000008877 Shoulder Dislocation Diseases 0.000 description 1
- 206010072610 Skeletal dysplasia Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000000123 anti-resoprtive effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000018678 bone mineralization Effects 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000018805 childhood acute lymphoblastic leukemia Diseases 0.000 description 1
- 201000011633 childhood acute lymphocytic leukemia Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 238000011393 cytotoxic chemotherapy Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- FMTDIUIBLCQGJB-SEYHBJAFSA-N demeclocycline Chemical compound C1([C@@H](O)[C@H]2C3)=C(Cl)C=CC(O)=C1C(=O)C2=C(O)[C@@]1(O)[C@@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C1=O FMTDIUIBLCQGJB-SEYHBJAFSA-N 0.000 description 1
- 229960002398 demeclocycline Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000005553 drilling Methods 0.000 description 1
- 238000009547 dual-energy X-ray absorptiometry Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 208000020089 femoral neck fracture Diseases 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 238000002639 hyperbaric oxygen therapy Methods 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000000281 joint capsule Anatomy 0.000 description 1
- 230000008407 joint function Effects 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000001582 osteoblastic effect Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 238000011422 pharmacological therapy Methods 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229910021426 porous silicon Inorganic materials 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 208000034133 primary 1 avascular necrosis of femoral head Diseases 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 208000037921 secondary disease Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000003966 vascular damage Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
- A61L2300/414—Growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Molecular Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPR2907A AUPR290701A0 (en) | 2001-02-06 | 2001-02-06 | A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis |
| AUPR4187A AUPR418701A0 (en) | 2001-04-03 | 2001-04-03 | A drug for use in bone grafting |
| AUPR6654A AUPR665401A0 (en) | 2001-07-27 | 2001-07-27 | A drug and method for the treatment of osteonecrosis |
| PCT/AU2001/001616 WO2002062351A1 (en) | 2001-02-06 | 2001-12-13 | A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK9862003A3 true SK9862003A3 (en) | 2004-02-03 |
Family
ID=27158265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK986-2003A SK9862003A3 (en) | 2001-02-06 | 2001-12-13 | A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US7425549B2 (cs) |
| EP (1) | EP1365769B1 (cs) |
| JP (1) | JP2004527479A (cs) |
| KR (1) | KR20030072399A (cs) |
| CN (1) | CN1233325C (cs) |
| AT (1) | ATE496624T1 (cs) |
| AU (1) | AU2002221339B2 (cs) |
| BR (1) | BR0116862A (cs) |
| CA (1) | CA2435552C (cs) |
| CY (1) | CY1111402T1 (cs) |
| CZ (1) | CZ301361B6 (cs) |
| DE (1) | DE60143964D1 (cs) |
| DK (1) | DK1365769T3 (cs) |
| HU (1) | HUP0303013A3 (cs) |
| IL (1) | IL157201A (cs) |
| MX (1) | MXPA03007029A (cs) |
| NO (1) | NO20033446L (cs) |
| NZ (1) | NZ527351A (cs) |
| PL (1) | PL361909A1 (cs) |
| SI (1) | SI1365769T1 (cs) |
| SK (1) | SK9862003A3 (cs) |
| WO (1) | WO2002062351A1 (cs) |
| ZA (1) | ZA200305890B (cs) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1365769T3 (da) * | 2001-02-06 | 2011-05-16 | Sydney Children S Hospitals Network Randwick And Westmead Incorporating The Royal Alexandra Hospital | Lægemiddel til behandling af osteonekrose og til behandling af patienter med risiko for at udvikle osteonekrose |
| NZ528659A (en) * | 2001-04-03 | 2005-02-25 | Royal Alexandra Hosp Children | A drug for use in bone grafting |
| CA2469779C (en) * | 2001-12-21 | 2008-02-12 | The Procter & Gamble Company | Method for the treatment of bone disorders |
| EP1506041B1 (en) * | 2002-05-10 | 2007-10-24 | F. Hoffmann-La Roche Ag | Ibandronic acid for the treatment and prevention of osteoporosis |
| CA2484494C (en) * | 2002-12-20 | 2009-05-12 | F. Hoffmann-La Roche Ag | High dose ibandronate formulation |
| ATE342722T1 (de) | 2003-05-07 | 2006-11-15 | Osteologix As | Behandlung von knorpel/knochen-erkrankungen mit wasserlöslichen strontiumsalzen |
| JPWO2005072747A1 (ja) * | 2004-02-02 | 2007-09-13 | 小野薬品工業株式会社 | 骨吸収抑制剤 |
| ITMI20040218A1 (it) * | 2004-02-10 | 2004-05-10 | Abiogen Pharma Spa | Uso di neridronato sodico per promuovere la neoformazione ossea |
| US20080167513A1 (en) | 2004-02-26 | 2008-07-10 | Osteologlx A/S | Strontium-Containing Compounds for Use in the Prevention or Treatment of Necrotic Bone Conditions |
| US7358361B2 (en) * | 2004-10-08 | 2008-04-15 | The Board Of Trustees Of The University Of Illinois | Biophosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases |
| US8012949B2 (en) * | 2004-10-08 | 2011-09-06 | The Board Of Trustees Of The University Of Illinois | Bisphosphonate compounds and methods with enhanced potency for multiple targets including FPPS, GGPPS, and DPPS |
| WO2006050493A2 (en) * | 2004-11-03 | 2006-05-11 | The Regents Of The University Of Michigan | Biodegradable implant for intertransverse process fusion |
| US8071574B2 (en) * | 2005-02-22 | 2011-12-06 | John Dennis Bobyn | Implant improving local bone formation |
| EP2001486A4 (en) * | 2006-03-17 | 2010-12-29 | Univ Illinois | BIPHOSPHONATE COMPOUNDS AND CORRESPONDING METHODS |
| US7833270B2 (en) * | 2006-05-05 | 2010-11-16 | Warsaw Orthopedic, Inc | Implant depots to deliver growth factors to treat osteoporotic bone |
| US8062364B1 (en) | 2007-04-27 | 2011-11-22 | Knee Creations, Llc | Osteoarthritis treatment and device |
| US9169279B2 (en) | 2009-07-31 | 2015-10-27 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| EP3295935B1 (en) | 2009-07-31 | 2020-07-22 | Grünenthal GmbH | Crystallization method and bioavailability |
| US20160016982A1 (en) | 2009-07-31 | 2016-01-21 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| WO2012071517A2 (en) | 2010-11-24 | 2012-05-31 | Thar Pharmaceuticals, Inc. | Novel crystalline forms |
| GB201200868D0 (en) | 2012-01-19 | 2012-02-29 | Depuy Int Ltd | Bone filler composition |
| WO2015060924A1 (en) * | 2013-10-25 | 2015-04-30 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating disease |
| WO2015200032A1 (en) | 2014-06-25 | 2015-12-30 | Spine Wave, Inc. | Minimally invasive posterolateral fusion |
| CN105012995B (zh) * | 2015-06-04 | 2018-03-09 | 武汉维斯第医用科技股份有限公司 | 一种含促骨愈合药物的胶原蛋白海绵及其制备方法 |
| US9775723B2 (en) | 2015-06-16 | 2017-10-03 | Spine Wave, Inc. | Instrument and system for placing graft, implant and graft material for minimally invasive posterolateral fusion |
| JP2019506386A (ja) * | 2016-01-14 | 2019-03-07 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Ｌｌｐ２ａ−ビスホスホネート化合物を用いて骨壊死を処置する方法 |
| US10195218B2 (en) | 2016-05-31 | 2019-02-05 | Grunenthal Gmbh | Crystallization method and bioavailability |
| AU2017204355B2 (en) | 2016-07-08 | 2021-09-09 | Mako Surgical Corp. | Scaffold for alloprosthetic composite implant |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2151240A1 (en) * | 1992-12-23 | 1994-07-07 | Donna T. Whiteford | Biophosphonate/estrogen therapy for treating and preventing bone loss |
| US5403829A (en) * | 1993-03-24 | 1995-04-04 | Leiras Oy | Use of bisphosphonates in endo-osteal bone surgery |
| US5646134A (en) * | 1994-04-21 | 1997-07-08 | Merck & Co., Inc. | Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices |
| US5476865A (en) * | 1994-07-06 | 1995-12-19 | Eli Lilly And Company | Methods of inhibiting bone loss |
| CN1113440A (zh) | 1994-07-29 | 1995-12-20 | 孟照强 | 一种治疗骨伤的中药制剂及其制备方法 |
| WO1996039974A1 (en) * | 1995-06-07 | 1996-12-19 | Implex Corporation | Femoral head core channel filling prosthesis |
| US7041641B2 (en) | 1997-03-20 | 2006-05-09 | Stryker Corporation | Osteogenic devices and methods of use thereof for repair of endochondral bone and osteochondral defects |
| US6316408B1 (en) * | 1997-04-16 | 2001-11-13 | Amgen Inc. | Methods of use for osetoprotegerin binding protein receptors |
| US5843678A (en) * | 1997-04-16 | 1998-12-01 | Amgen Inc. | Osteoprotegerin binding proteins |
| AU750803B2 (en) | 1997-10-29 | 2002-07-25 | University Of Pittsburgh | Use of vectors such as adenoviruses and/or adeno associated viruses and/or retroviruses and/or herpes simplex viruses and/or liposomes and/or plasmids as a vehicle for genetic information enabling mammal cells to produce agents for the treatment of bone pathologies |
| US6268367B1 (en) * | 1998-02-23 | 2001-07-31 | Zymogenetics, Inc. | Piperazine derivatives for treating bone deficit conditions |
| EP1121133A1 (en) | 1998-10-15 | 2001-08-08 | Merck & Co., Inc. | Methods for stimulating bone formation |
| IL146520A0 (en) * | 1999-05-21 | 2002-07-25 | Novartis Ag | Use of bisphosphonic acids for treating angiogenesis |
| AU781068B2 (en) * | 1999-08-19 | 2005-05-05 | Sydney Children's Hospitals Network (Randwick and Westmead) (incorporating The Royal Alexandra Hospital for Children), The | Drug for treating fractures |
| AUPQ232599A0 (en) | 1999-08-19 | 1999-09-09 | Royal Alexandra Hospital For Children, The | Drug for treating fractures |
| US6482411B1 (en) * | 1999-08-27 | 2002-11-19 | Board Of Regents, The University Of Texas System | Methods of reducing bone loss with CD40 ligand |
| GB0029111D0 (en) | 2000-11-29 | 2001-01-10 | Novartis Ag | Organic compounds |
| DK1365769T3 (da) * | 2001-02-06 | 2011-05-16 | Sydney Children S Hospitals Network Randwick And Westmead Incorporating The Royal Alexandra Hospital | Lægemiddel til behandling af osteonekrose og til behandling af patienter med risiko for at udvikle osteonekrose |
| AUPR553701A0 (en) | 2001-06-07 | 2001-07-12 | Royal Alexandra Hospital For Children, The | A device for the delivery of a drug to a fractured bone |
-
2001
- 2001-12-13 DK DK01273650.0T patent/DK1365769T3/da active
- 2001-12-13 DE DE60143964T patent/DE60143964D1/de not_active Expired - Lifetime
- 2001-12-13 NZ NZ527351A patent/NZ527351A/en not_active IP Right Cessation
- 2001-12-13 WO PCT/AU2001/001616 patent/WO2002062351A1/en active IP Right Grant
- 2001-12-13 US US10/470,924 patent/US7425549B2/en not_active Expired - Fee Related
- 2001-12-13 CA CA2435552A patent/CA2435552C/en not_active Expired - Fee Related
- 2001-12-13 SK SK986-2003A patent/SK9862003A3/sk unknown
- 2001-12-13 SI SI200130991T patent/SI1365769T1/sl unknown
- 2001-12-13 CZ CZ20032408A patent/CZ301361B6/cs not_active IP Right Cessation
- 2001-12-13 AT AT01273650T patent/ATE496624T1/de active
- 2001-12-13 MX MXPA03007029A patent/MXPA03007029A/es active IP Right Grant
- 2001-12-13 KR KR10-2003-7010328A patent/KR20030072399A/ko not_active Ceased
- 2001-12-13 BR BR0116862-2A patent/BR0116862A/pt not_active Application Discontinuation
- 2001-12-13 AU AU2002221339A patent/AU2002221339B2/en not_active Ceased
- 2001-12-13 CN CNB018225365A patent/CN1233325C/zh not_active Expired - Fee Related
- 2001-12-13 JP JP2002562358A patent/JP2004527479A/ja active Pending
- 2001-12-13 HU HU0303013A patent/HUP0303013A3/hu unknown
- 2001-12-13 EP EP01273650A patent/EP1365769B1/en not_active Expired - Lifetime
- 2001-12-13 PL PL36190901A patent/PL361909A1/xx not_active IP Right Cessation
-
2003
- 2003-07-30 ZA ZA2003/05890A patent/ZA200305890B/en unknown
- 2003-07-31 IL IL157201A patent/IL157201A/en not_active IP Right Cessation
- 2003-08-04 NO NO20033446A patent/NO20033446L/no not_active Application Discontinuation
-
2008
- 2008-08-13 US US12/191,264 patent/US7612050B2/en not_active Expired - Fee Related
-
2011
- 2011-04-20 CY CY20111100406T patent/CY1111402T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US7425549B2 (en) | 2008-09-16 |
| NO20033446D0 (no) | 2003-08-04 |
| EP1365769A4 (en) | 2005-08-10 |
| AU2002221339B2 (en) | 2006-04-27 |
| WO2002062351A1 (en) | 2002-08-15 |
| ZA200305890B (en) | 2005-01-26 |
| NO20033446L (no) | 2003-10-01 |
| US20040097469A1 (en) | 2004-05-20 |
| SI1365769T1 (sl) | 2011-06-30 |
| CN1529604A (zh) | 2004-09-15 |
| IL157201A (en) | 2010-04-29 |
| CY1111402T1 (el) | 2015-08-05 |
| BR0116862A (pt) | 2004-01-13 |
| DE60143964D1 (de) | 2011-03-10 |
| EP1365769B1 (en) | 2011-01-26 |
| CN1233325C (zh) | 2005-12-28 |
| CZ20032408A3 (cs) | 2004-06-16 |
| HUP0303013A3 (en) | 2007-06-28 |
| CA2435552A1 (en) | 2002-08-15 |
| JP2004527479A (ja) | 2004-09-09 |
| NZ527351A (en) | 2005-01-28 |
| KR20030072399A (ko) | 2003-09-13 |
| PL361909A1 (en) | 2004-10-04 |
| HUP0303013A2 (hu) | 2003-12-29 |
| US7612050B2 (en) | 2009-11-03 |
| HK1061797A1 (en) | 2004-10-08 |
| DK1365769T3 (da) | 2011-05-16 |
| MXPA03007029A (es) | 2004-10-15 |
| CA2435552C (en) | 2010-04-27 |
| CZ301361B6 (cs) | 2010-01-27 |
| US20090005347A1 (en) | 2009-01-01 |
| ATE496624T1 (de) | 2011-02-15 |
| EP1365769A1 (en) | 2003-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK9862003A3 (en) | A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis | |
| AU2002221339A1 (en) | A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis | |
| CN1078073C (zh) | 二膦酸盐在矫形假体移植后在抑制骨再吸收中的应用 | |
| AU2002244520B2 (en) | A drug for use in bone grafting | |
| AU2002244520A1 (en) | A drug for use in bone grafting | |
| WO2002098307A1 (en) | A device for the delivery of a drug to a fractured bone | |
| JP2024037985A (ja) | 人工骨膜 | |
| Tekin et al. | Effects of alendronate on rate of distraction in rabbit mandibles | |
| RU2284821C2 (ru) | Лекарственное средство для лечения остеонекроза и для лечения пациентов с риском развития остеонекроза | |
| ES2362024T3 (es) | Fármaco para el tratamiento de osteonecrosis para la gestión de pacientes con riesgo de desarrollar osteonecrosis. | |
| HK1061797B (en) | A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TC4A | Change of owner's name |
Owner name: THE SYDNEY CHILDREN S HOSPITALS NETWORK (RANDW, AU Effective date: 20101213 |
|
| FB9A | Suspension of patent application procedure |